GlassScriptPhysician profile
Carlos Perez
NPI 1033229661
$8,905.35
in general payments reported to CMS, 2019-2025
25 companies · $2,201 in 2025
The $2,201 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $165 · 2021: $591 · 2022: $1,237 · 2023: $2,085 · 2024: $1,907 · 2025: $2,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,187 · Education: $5.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,187.46 |
| Education | $5.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,564.14 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $1,416.32 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,080.49 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $644.73 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Alkermes, INC. | $621.80 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $578.18 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $481.43 | 2019-2025 | Trintellix |
| Abbvie INC. | $415.83 | 2021-2025 | |
| Axsome Therapeutics, INC. | $382.92 | 2023-2025 | Auvelity |
| Lundbeck LLC | $348.30 | 2019-2025 | Rexulti, Brintellix |
| Almatica Pharma LLC | $313.94 | 2022-2025 | Loreev Xr |
| Avanir Pharmaceuticals, INC. | $239.33 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $185.62 | 2024-2025 | Fanapt |
| Allergan, INC. | $160.20 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $87.41 | 2023-2025 | Qelbree, Qelbree |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $62.29 | 2020-2024 | Freestyle Libre 3 |
| Corium, LLC | $57.67 | 2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $55.74 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $50.29 | 2024-2025 | Cobenfy |
| Astrazeneca Pharmaceuticals LP | $39.91 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $37.83 | 2023 | Quviviq |
| Eisai INC. | $26.95 | 2021-2022 | |
| Glaxosmithkline, LLC. | $23.07 | 2023 | Shingrix |
| Bausch Health US, LLC | $15.67 | 2022 | |
| Merck Sharp & Dohme LLC | $15.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.